A-183 Base Rates of Performance and Symptom Validity Test Failures in Active Duty and Veteran Samples Referred for Attention-Deficit/Hyperactivity Disorder Evaluation

2021 ◽  
Vol 36 (6) ◽  
pp. 1238-1238
Author(s):  
Robert D Shura ◽  
Patrick Armistead-Jehle ◽  
Douglas B Cooper

Abstract Objective To evaluate base rates of abnormal MMPI-2-RF symptom validity test (SVT) and stand-alone performance validity test (PVT) scores in active duty (ad) service member and Veterans Affairs clinical samples referred for neuropsychological assessment of ADHD. Method MMPI-2-RF SVT scores and various PVTs were evaluated in two samples referred specifically for assessment of ADHD: service members (N = 82) and Veterans (N = 355). SVT and PVT outcomes were then compared to published data establishing invalid base rates in larger, more general samples. Results Elevated MMPI-2-RF overreport scales (F-r ≥ 79; FS, RBS, and FBS-r ≥ 80; & Fp-r ≥ 70) ranged from 14.6% (FBS-r) to 40.0% (RBS) in the ad sample and 12.0% (FBS-r) and 28.9% (RBS) in the veteran sample. MMPI-2-RF profiles that were invalidated due to overreport (e.g., F-r = 120, all others ≥100) were under 5% on the veteran sample and no greater than 6.1% in the ad sample. Elevations on underreport scales were higher in the veteran sample (L-r = 12.9%, K-r = 2.0%) than the ad sample (L-r = 3.7%, K-r = 1.2%). In the ad sample, 21.5% failed one PVT and 6.3% failed two. In the Veteran sample, 23.4% failed one PVT. Conclusions Elevated MMPI-2-RF overreport scales were relatively common on ad and Veterans referred for ADHD evaluations. However, frequencies of elevated and invalidated scales were diminished relative to overall base rates reported in national data. Regarding PVT failure, both samples were lower than national average invalid rates. Despite the incentive inherent in ADHD exams, invalidity in both samples were consistently lower for both SVTs and PVTs.

Author(s):  
Jacobus Donders ◽  
Nathan Lefebre ◽  
Rachael Goldsworthy

Abstract Objective The purpose of this study was to evaluate the presence of demographic, injury and neuropsychological correlates of distinct patterns of performance validity test and symptom validity test results in persons with mild traumatic brain injury (mTBI). Method One hundred and seventy-eight persons with mTBI completed the Test of Memory Malingering (TOMM; performance validity) and the Minnesota Multiphasic Personality Inventory-2-Restructured Form (MMPI-2-RF; symptom validity) within 1–12 months postinjury. Four groups were compared: (a) pass both TOMM and MMPI-2-RF validity criteria, (b) pass TOMM and fail MMPI-2-RF, (c) fail TOMM and pass MMPI-2-RF, and (d) fail both TOMM and MMPI-2-RF. Results Compared to Group a, participants in combined Groups b–d were more than twice as likely to be engaged in financial compensation-seeking and about four times less likely to have neuroimaging evidence of an intracranial lesion. The average performance of Group d on an independent test of verbal learning was more than 1.5 standard deviations below that of Group a. Participants in Group b were more likely to have intracranial lesions on neuroimaging than participants in Group c. Conclusion Performance and symptom validity tests provide complementary and non-redundant information in persons with mTBI. Whereas financial compensation-seeking is associated with increased risk of failure of either PVT or SVT, or both, the presence of intracranial findings on neuroimaging is associated with decreased risk of such.


Assessment ◽  
2020 ◽  
pp. 107319112098391
Author(s):  
Zachary J. Resch ◽  
Tasha Rhoads ◽  
Gabriel P. Ovsiew ◽  
Jason R. Soble

This study cross-validated the Medical Symptom Validity Test (MSVT) in a mixed neuropsychiatric sample and examined its accuracy for identifying invalid neuropsychological performance using a known-groups design. Cross-sectional data from 129 clinical patients who completed the MSVT were examined. Validity groups were established using six, independent criterion performance validity tests, which yielded 98 patients in the valid group and 31 in the invalid group. All MSVT subtest scores were significantly lower in the invalid group (η p2=.22-.39). Using published cut-scores, sensitivities of 42% to 71% were found among the primary effort subtests, and 74% sensitivity/90% specificity was observed for the overall MSVT. Among this sample, the MSVT component validity scales produced areas under the curve of .78-.86, suggesting moderate classification accuracy. At optimal cut-scores, the MSVT primary effort validity scales demonstrated 55% to 71% sensitivity/91% to 93% specificity, with the Consistency subtest exhibiting the strongest psychometric properties. The MSVT exhibited relatively robust sensitivity and specificity, supporting its utility as a briefer freestanding performance validity test to its predecessor, the Word Memory Test. Finally, the Genuine Memory Impairment Profile appears promising for patients with Major Neurocognitive Disorder, but is cautioned against for those without significant functional decline in activities of daily living at this time.


2020 ◽  
Vol 35 (7) ◽  
pp. 1162-1167
Author(s):  
Patrick Armistead-Jehle ◽  
Sara M Lippa ◽  
Chad E Grills

Abstract Objective Recent research has examined potential influences to performance validity testing beyond intentional feigning. The current study sought to examine the hypothesized relationships of two psychological constructs (self-efficacy and health locus of control) with performance validity testing (PVT). Method Retrospective review of 158 mild traumatic brain injury (mTBI) cases referred to an Army outpatient clinic for neuropsychological evaluation. The mTBI cases were classified according to passing or failing the Medical Symptom Validity Test (MSVT) or Non-Verbal Medical Symptom Validity Test (NV-MSVT). Group comparisons were performed utilizing one-way ANOVA to evaluate the differences between the PVT-Pass and PVT-Fail groups on self-efficacy (MMPI-2-RF Inefficacy scale) and locus of control (Multi-Dimensional Health Locus of Control). Results There was no relationship between self-efficacy or health locus of control and passing/failing PVTs. Conclusions Further research is warranted to explore potential influences on PVT performance, which we conceptualize as analogous to experimental nuisance variables that may be amenable to intervention.


2019 ◽  
Vol 34 (6) ◽  
pp. 935-935
Author(s):  
E Ringdahl ◽  
R Seegmiller ◽  
J Aden ◽  
C Stephens

Abstract Objective The Green’s Medical Symptom Validity Test (MSVT) is a measure of performance validity and has a formula to help distinguish genuine cognitive impairment from suboptimal engagement. The current study used the MSVT “dementia profile” formula to discriminate patients with no neurocognitive disorder (no NCD), mild neurocognitive disorder (mild NCD), and major neurocognitive disorder (major NCD). Method 198 patients who were seen for comprehensive outpatient neuropsychological testing and passed all MSVT validity measures were included in the study. Specifically, participants included 103 persons with no NCD, 62 diagnosed with a mild NCD, and 33 with major NCD, who were collectively 58% male, with a mean age of 52-years-old (SD = 16.1) and mean education of 14.5 years (SD = 2.5). Results The difference score between easy and hard MSVT subtests predicted group assignment (r = .57, p < .001) and effectively differentiated the three groups (p < .001). Mean difference scores of both groups with diagnosed NCD exceeded recommended criteria suggestive of genuine cognitive impairment, with the differences score of major NCD being greater (p < .01) than the mild NCD. Group differences remained significant (p < .001) after adjusting for the effects of age and education. When the NCD groups were compared to the no diagnosis group, ROC curve analysis produced an AUC of .84, with a sensitivity of .72 and specificity of .83. Conclusions Findings from this study validate the established difference score between easy and hard subtests of the MSVT, and suggest that the difference score on a valid MSVT profile yields diagnostically relevant information pertaining to the level of an individual’s neurocognitive impairment.


2020 ◽  
Vol 35 (6) ◽  
pp. 1019-1019
Author(s):  
Link J ◽  
Lu L ◽  
Armistead-Jehle P ◽  
Seegmiller R

Abstract Objective Previously, the Grooved Pegboard Test (GPB) has shown potential as an embedded measure of performance validity (PVT) using a T-score cutoff for either hand (≤ 29) or both hands (≤ 31). This study sought to validate these cutoffs with established PVTs (Medical Symptom Validity Test [MSVT], Non-Verbal Medical Symptom Validity Test [NV-MSVT], and Reliable Digit Span [RDS]). Method Subjects (N = 190) were primarily Caucasian (85%) and male (81%). Average age and education were 41 (SD = 11.62) and 16 years (SD = 2.35), respectively. Participants were stratified as GPB “pass or fail” based on previously proposed cutoff criteria. MSVT, NV-MSVT, and RDS were also dichotomized as pass or fail based on manual or conventional recommendations. Results Chi-Square analyses revealed significant associations between GPB “fails” for both hands and MSVT, NV-MSVT, and RDS (χ2 (1, n = 190) ranging from 5.80 to 15.98, Phi ranging from .18 to .29, p ranging from &lt; .05 to &lt; .0001). Similar findings were observed for dominant hand “fails”; however, non-dominant hand was only related to the MSVT. Sensitivity and specificity values from the GPB measures ranged from .47 to .58 and from .89 to .92, respectively. Positive and negative predictive power ranged from .38 to .45 and .93 to .94, respectively. Conclusion These data demonstrate the relative utility of the GPB as an embedded PVT. In particular, dominant and both hand cutoffs are likely to be more clinically useful in determining sub-optimal performance. However, as sensitivity is relatively low, this measure should not be employed as the sole PVT administered.


Author(s):  
Zachary J. Resch ◽  
Troy A. Webber ◽  
Matthew T. Bernstein ◽  
Tasha Rhoads ◽  
Gabriel P. Ovsiew ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document